Semaglutide (15 mg Vial) Dosage Protocol

Supplies Needed

Clear 12-week and 24-week planning for a 15 mg vial at 5 mg/mL.

• Semaglutide vials (15 mg each):
  • 12-week schedule: 1 vial needed. Total scheduled amount: 7 mg.
  • 24-week schedule: 3 vials needed. Total scheduled amount: 33 mg.
• U-100 insulin syringes (1 mL capacity):
  • 12-week schedule: 12 new syringes needed.
  • 24-week schedule: 24 new syringes needed.
• Documented sterile diluent (10 mL bottles):
  • 12-week schedule: 1 bottle needed. Total diluent volume: 3 mL.
  • 24-week schedule: 1 bottle needed. Total diluent volume: 9 mL.
• Alcohol swabs:
  • 12-week schedule: 24 swabs minimum. 1 box of 100 covers this minimum.
  • 24-week schedule: 48 swabs minimum. 1 box of 100 covers this minimum.
• Sharps container: One appropriately sized container for used syringes.

Stability planning: Vial, syringe, swab, and diluent totals are minimum arithmetic quantities for the standard schedule shown. Follow the exact product documentation for sterility, storage, handling loss, and discard timing.

Important Notes

Practical details for reading the schedule and vial calculations consistently.

• The weekly amounts are identical across every Semaglutide vial-size page. Only concentration, volume, U-100 units, and supply totals change.
• The injectable schedule uses four-week escalation steps before the usual 2.4 mg adult weight-reduction maintenance amount.^[1][2][3][4]
• The current label also allows an increase to 7.2 mg once weekly after at least four weeks at 2.4 mg when additional weight reduction is clinically indicated; that optional amount is not included in the standard table or supply totals.^[1][8]
• Use a new sterile syringe for each injection and place used sharps in an appropriate container.^[11][12]
• Record the weekly amount, calculated units, volume, date, and administration site consistently.

How This Works

Semaglutide is a GLP-1 receptor agonist studied with once-weekly subcutaneous schedules in controlled human trials.^[1][2][4][9]

• GLP-1 receptor activity contributes to glucose-dependent insulin signaling, glucagon regulation, appetite signaling, and caloric intake.^[1][9]
• The extended pharmacokinetic profile supports once-weekly administration in the cited clinical programs.^[1][2][4][9]
• The published trials evaluated manufactured study products with structured escalation and monitoring plans.^[2][3][4][5]

Clinical Benefits

Results below summarize observations from controlled human research.

• STEP 1 reported clinically meaningful body-weight reductions with 2.4 mg once-weekly semaglutide plus lifestyle intervention through 68 weeks.^[2][3]
• STEP 2 reported body-weight improvement in adults with overweight or obesity and type 2 diabetes at the studied 2.4 mg weekly target.^[4]
• STEP 4 reported continued weight reduction when weekly 2.4 mg treatment continued after the 20-week run-in period.^[5][10]
• SELECT and SUSTAIN-6 evaluated cardiovascular outcomes in distinct high-risk study populations.^[6][7]

Side Effects

Safety findings remain specific to the studied populations, products, schedules, and monitoring plans.

• Gastrointestinal events, including nausea, diarrhea, vomiting, and constipation, were among the commonly reported events.^[1][2][4][5]
• Gradual escalation is used to reduce gastrointestinal adverse reactions in the current prescribing information.^[1]
• The current prescribing information includes contraindications, warnings, precautions, and interaction information that should be read in full.^[1]
• Trial results should be compared within the same population, target amount, follow-up period, and analysis plan.

Lifestyle Factors

Consistent study conditions make weekly observations easier to interpret.

• Record diet, physical activity, sleep, hydration, and gastrointestinal observations consistently.
• Use the same body-weight, waist, glucose, and laboratory measurement methods throughout the observation period.
• Compare results within the same population, target amount, follow-up period, and analysis plan.

Injection Technique

General subcutaneous research technique should follow the approved institutional or laboratory procedure.^[11][12]

• Use a new sterile syringe and needle for every injection and each separate vial entry.
• Clean the vial stopper and selected site, then allow the surface to dry.
• Use the needle length, angle, and skinfold method specified by the governing procedure.
• Rotate sites systematically and document each administration.
• Place used sharps immediately in an appropriate sharps container.